Molecular structure of ZM 336372, CAS Number: 208260-29-1
ZM 336372 (CAS 208260-29-1)
See product citations (2)
Alternate Names:
3-(Dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]-benzamide
Application:
ZM 336372 is a potent and selective Raf-1 inhibitor
CAS Number:
208260-29-1
Purity:
≥95%
Molecular Weight:
389.45
Molecular Formula:
C23H23N3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
ZM 336372 is a reversible, selective inhibitor of the protein kinase Raf-1. Although ZM 336372 weakly inhibits Raf-B, it is 10 fold more potent against Raf-1 and so is considered more selective towards this kinase. ZM 336372 inhibits Raf-1 by competing with ATP to bind to the protein. Alternate studies suggest that ZM 336372 can induce apoptosis in pancreatic adenocarcinoma cell lines by inhibiting glycogen synthase kinase-3beta (GSK-3beta) through phosphorylation of GSK-3beta at Ser 9. ZM 336372 can suppress the proliferation of hepatocellular carcinoma cells by inhibiting hormone secretion and up-regulating cell cycle inhibitors. ZM 336372 can also act as an agonist towards Raf-1, activating the MAPK pathway, which can be suppressed after activation by Raf-1 itself, using a novel feedback loop in which activation is always followed by inactivation. ZM 336372 is an inhibitor of p38 alpha and p38 beta.
ZM 336372 (CAS 208260-29-1) References
- Paradoxical activation of Raf by a novel Raf inhibitor. | Hall-Jackson, CA., et al. 1999. Chem Biol. 6: 559-68. PMID: 10421767
- Mechanism of fluoride-induced MAP kinase activation in pulmonary artery endothelial cells. | Bogatcheva, NV., et al. 2006. Am J Physiol Lung Cell Mol Physiol. 290: L1139-45. PMID: 16414982
- 1Alpha,25-dihydroxyvitamin D3-mediated stimulation of steroid sulphatase activity in myeloid leukaemic cell lines requires VDRnuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway. | Hughes, PJ. and Brown, G. 2006. J Cell Biochem. 98: 590-617. PMID: 16440327
- ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line. | Deming, D., et al. 2008. J Gastrointest Surg. 12: 852-7. PMID: 18299943
- MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype. | Chen, JY., et al. 2010. J Surg Res. 158: 15-9. PMID: 19765735
- ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. | Deming, D., et al. 2010. J Surg Res. 161: 28-32. PMID: 20031160
- Raf-1 kinase regulates smooth muscle contraction in the rat mesenteric arteries. | Sathishkumar, K., et al. 2010. J Vasc Res. 47: 384-98. PMID: 20110729
- Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer. | Cook, MR., et al. 2010. Am J Surg. 199: 315-8; discussion 318. PMID: 20226902
- Emerging therapies for advanced gastroenteropancreatic neuroendocrine tumors. | Gupta, S., et al. 2011. Clin Colorectal Cancer. 10: 298-309. PMID: 21813338
- The preclinical development of regorafenib for the treatment of colorectal cancer. | Miura, K., et al. 2014. Expert Opin Drug Discov. 9: 1087-101. PMID: 24896071
- Involvement of mitogen-activated protein kinase pathway in T-2 toxin-induced cell cycle alteration and apoptosis in human neuroblastoma cells. | Agrawal, M., et al. 2015. Mol Neurobiol. 51: 1379-94. PMID: 25084755
- ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer. | Hasegawa, T., et al. 2017. FEBS Open Bio. 7: 1154-1165. PMID: 28781955
- Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. | Saei, A. and Eichhorn, PJA. 2019. Cancers (Basel). 11: PMID: 31416288
- Three-Dimensional Cell Cultures as an In Vitro Tool for Prostate Cancer Modeling and Drug Discovery. | Fontana, F., et al. 2020. Int J Mol Sci. 21: PMID: 32948069
- Drug Repositioning Identifies Six Drug Candidates for Systemic Autoimmune Diseases by Integrative Analyses of Transcriptomes from Scleroderma, Systemic Lupus Erythematosus, and Sjogren's Syndrome. | Oktem, EK. and Yazar, M. 2022. OMICS. 26: 683-693. PMID: 36378860
Inhibitor of:
4932411E22Rik, 4933412E24Rik, 5830411N06Rik, 6430706D22Rik, 8430426H19Rik, 9130017N09Rik, 9130404D08Rik, ABTB1, ACN9, AD031, AGPHD1, AI314976, AI467606, AKD1, ANKIB1, ANKRD25, ANKRD30A, ANKRD34C, ANKRD50, AP-2ε, ARL10, ARMCX2, ASB-18, BTBD16, BTNL3, C10orf32, C10orf95, C130090K23Rik, C14orf165, C14orf177, C14orf54, C14orf73, C16orf47, C1orf172_1810019J16Rik, C20orf4, C5orf23, C5orf40, C9orf38, CCDC122, CCDC14, CCDC142, CCDC73, CCDC9, Ccr1l1, CDV3, CHIC1, cortexin 3, CR16, CTGLF1, CXorf26, CXorf58, DBT, DECR2, Deltex-3, DHRSX, DPCD, DTHD1, EAT2, EG668339, ESSPL, FAAP, FAM154B, FLJ21986, FNDC8, G0S2, GAGE2D, GLTSCR1, GRRP1, HEATR7A, HOP-1, INTS12, LACTB, LACTBL1, LOC100041215, LOC100041220, LOC100041249, LOC284215, LOC339209, LOC388284, LOC391742, LOC439949, LOC441294, LOC644477, LOC646103, LOC649198, LOC727903, LRRC57, MACROD2, Maestro, MEMO1, METT5D1, MGC42105, NBPF12, NKp30, Nkx-2.8, Noxp20, OR4D11, OR4P4, p38 alpha, PAPP-A, PERLD1, PILR-β, Pira11, PRAME like-7, PRAMEF8, Pramel, promethin, PTAR1, PTX4, Rab 25, Rab11-FIP3, Raf-1, Rap 2A, RASSF4, RBM33, RG9MTD2, RIBC1, SBF2, SBNO1, Ser/Thr Protein Kinase, SIT, SLA/LP, Slx, SmcY, SMR3B, SPACR, SPANX-E, SPATA20, SPEER-4A, SPEER-4F, SPIN3, SPIN4, TBC1D3F, TESSP-1, TG1019, THAP10, TMEM104, TPRG1, V1RC16, V1RE2, Vgl-2, VLP, WDR87, XKRX, ZNF185, ZNF347, and ZNF484.Activator of:
β-glucosidase 2, ABCE1, AKR1C20, BCA3, ENL, ENSMUSG00000071517, MINK1, NUDT21, Ost, Reprimo, TAF9A, and Tom1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ZM 336372, 1 mg | sc-202857 | 1 mg | $47.00 |